JY232

· Shenzhen Genocury Biotech Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JY232, covering 2026-01-13 to 2026-01-13. Get the full timeline:

Most recent: Clinical Trial Update: JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]